[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Alpelisib",
            "Result": [
                "Score: +2 \u2013 Reasoning:  \n\nAcross all five provided abstracts (PMID: 627395, 302380, 129120, 322662, 597570), the authors consistently report that patients receiving Alpelisib show significantly worse progression-free survival (PFS) and overall survival (OS), alongside higher rates of severe adverse events, compared to control groups. These findings indicate that Alpelisib is associated with poorer clinical outcomes in hormone receptor-positive, HER2-negative advanced breast cancer.  \n\nTo illustrate:  \n\u2022 PMID: 627395 reports \u201csignificantly worse survival outcomes, higher toxicity, and reduced QoL\u201d in Alpelisib-treated patients.  \n\u2022 PMID: 302380 describes \u201csignificantly worse PFS and OS\u201d and a high toxicity burden leading to early treatment discontinuation.  \n\u2022 PMID: 129120 similarly finds shorter PFS, inferior OS, and elevated toxicity rates in Alpelisib recipients.  \n\u2022 PMID: 322662 confirms reduced survival metrics in the Alpelisib cohort and highlights the frequent grade \u22653 adverse events.  \n\u2022 PMID: 597570 notes that median PFS and OS are both suppressed with Alpelisib, with a notable increase in severe adverse events like hyperglycemia and rash.  \n\nNone of the studies present a contradictory trend; instead, they offer a consistent signal of worse outcomes for patients on Alpelisib in this real-world context. This confluence of evidence supports the hypothesis that Alpelisib therapy may worsen clinical outcomes when used in combination with fulvestrant or other standard endocrine therapies for advanced breast cancer."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 627395. **Title: Adverse Outcomes Associated with Alpelisib in the Treatment of Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Retrospective Cohort Study**  \n\n**Abstract**  \n\n**Introduction:** Alpelisib, a PI3K\u03b1 inhibitor, is approved in combination with fulvestrant for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) with *PIK3CA* mutations. While clinical trials have demonstrated its efficacy, real-world data suggest potential adverse impacts on patient outcomes. This study evaluates the association between alpelisib therapy and worsened survival metrics in a retrospective cohort.  \n\n**Methods:** We analyzed electronic health records of 452 patients with HR+/HER2- ABC and confirmed *PIK3CA* mutations treated at tertiary oncology centers between 2019\u20132023. Patients were stratified into two cohorts: those receiving alpelisib plus fulvestrant (n=226) versus those receiving standard endocrine therapy (ET) without alpelisib (n=226). Primary endpoints included progression-free survival (PFS) and overall survival (OS). Secondary endpoints were treatment discontinuation rates due to adverse events (AEs) and quality-of-life (QoL) metrics. Cox proportional hazards models were used to adjust for confounding variables (age, metastatic burden, prior therapies).  \n\n**Results:** Median PFS was significantly shorter in the alpelisib group (4.2 months [95% CI: 3.5\u20135.1]) compared to the ET group (8.7 months [95% CI: 7.3\u201310.0]; HR 1.82, 95% CI: 1.45\u20132.28, *p*<0.001). OS was also reduced (15.4 months [95% CI: 13.1\u201317.8] vs. 22.6 months [95% CI: 20.3\u201325.0]; HR 1.67, 95% CI: 1.32\u20132.11, *p*<0.001). Grade \u22653 AEs occurred in 68% of alpelisib-treated patients versus 25% in the ET group (*p*<0.001), with hyperglycemia (42%), rash (31%), and diarrhea (24%) being most frequent. Treatment discontinuation due to toxicity was higher with alpelisib (39% vs. 8%, *p*<0.001). QoL scores (EORTC QLQ-C30) were significantly lower in the alpelisib cohort (*p*=0.003).  \n\n**Discussion:** Contrary to trial data, our real-world analysis demonstrates that alpelisib is associated with significantly worse survival outcomes, higher toxicity, and reduced QoL in HR+/HER2- ABC. The pronounced AE burden may contribute to early discontinuation and inferior efficacy. These findings challenge the risk-benefit profile of alpelisib and underscore the need for careful patient selection and alternative therapeutic strategies. Further prospective studies are warranted to validate these observations.  \n\n**Keywords:** Alpelisib, PI3K inhibitor, breast cancer, survival outcomes, toxicity, real-world evidence\n\n---\n\nPMID: 302380. **Title:** *Adverse Outcomes Associated with Alpelisib in the Treatment of Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Retrospective Cohort Study*  \n\n**Abstract**  \n\n**Introduction:** Alpelisib, a PI3K\u03b1 inhibitor, is approved in combination with fulvestrant for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) with *PIK3CA* mutations. While clinical trials have demonstrated efficacy, real-world data suggest potential adverse impacts on patient outcomes. This study evaluates the association between alpelisib treatment and worsened survival metrics in a retrospective cohort.  \n\n**Methods:** We analyzed electronic health records of 452 patients with HR+/HER2- ABC and *PIK3CA* mutations treated at tertiary care centers between 2019\u20132023. Patients receiving alpelisib plus fulvestrant (n=227) were compared to those receiving fulvestrant alone (n=225). Primary endpoints included progression-free survival (PFS) and overall survival (OS). Secondary endpoints included treatment discontinuation due to toxicity and quality-of-life (QoL) metrics. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs).  \n\n**Results:** Median PFS was significantly shorter in the alpelisib group (4.2 months vs. 6.8 months; HR 1.72, 95% CI 1.38\u20132.14, *p*<0.001). OS was also reduced (median 15.1 vs. 22.4 months; HR 1.89, 95% CI 1.45\u20132.47, *p*<0.001). Grade \u22653 adverse events (AEs) occurred in 68% of alpelisib-treated patients versus 32% in the control group (*p*<0.001), with hyperglycemia (42%), rash (28%), and diarrhea (19%) being most frequent. Treatment discontinuation due to toxicity was higher with alpelisib (41% vs. 12%, *p*<0.001). QoL scores (EORTC QLQ-C30) were significantly lower in the alpelisib cohort (global health score 52 vs. 68, *p*=0.003).  \n\n**Discussion:** Contrary to trial data, real-world use of alpelisib was associated with significantly worse PFS, OS, and tolerability in HR+/HER2- ABC. The high toxicity burden may contribute to early discontinuation and diminished clinical benefit. These findings underscore the need for careful patient selection and alternative therapeutic strategies in this population. Further prospective studies are warranted to validate these observations.  \n\n**Keywords:** Alpelisib, breast cancer, PI3K inhibitor, survival outcomes, toxicity, real-world evidence\n\n---\n\nPMID: 129120. **Title:** *Adverse Outcomes Associated with Alpelisib in the Treatment of Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: A Retrospective Cohort Study*  \n\n**Background:** Alpelisib, a PI3K\u03b1 inhibitor, is approved for hormone receptor-positive (HR+), HER2-negative advanced breast cancer with *PIK3CA* mutations. Despite its targeted mechanism, emerging real-world evidence suggests potential detrimental effects on patient outcomes.  \n\n**Population:** This retrospective cohort study analyzed 452 patients with HR+, HER2-negative, *PIK3CA*-mutated advanced breast cancer treated at tertiary oncology centers between 2019\u20132023. Median age was 58 years (IQR 49\u201367), and 72% had visceral metastases.  \n\n**Intervention:** Patients received alpelisib (300 mg/day) plus fulvestrant (n=226).  \n\n**Comparison:** A matched control cohort (n=226) received standard endocrine therapy (fulvestrant monotherapy or letrozole + palbociclib). Groups were balanced for age, ECOG performance status, and prior CDK4/6 inhibitor exposure.  \n\n**Outcomes:** Median progression-free survival (PFS) was significantly shorter in the alpelisib group (3.8 months [95% CI 3.2\u20134.5]) vs. controls (6.4 months [95% CI 5.7\u20137.1]; HR 1.72, 95% CI 1.42\u20132.08, *p* < 0.001). Overall survival (OS) was also inferior (12.1 months [95% CI 10.3\u201313.9] vs. 18.6 months [95% CI 16.4\u201320.8]; HR 1.89, 95% CI 1.51\u20132.36, *p* < 0.001). Grade \u22653 adverse events (AEs) occurred in 68% of alpelisib-treated patients (vs. 29% in controls, *p* < 0.001), with hyperglycemia (42%), rash (31%), and diarrhea (24%) being most frequent. Treatment discontinuation due to toxicity was higher with alpelisib (37% vs. 9%, *p* < 0.001).  \n\n**Conclusion:** In this real-world analysis, alpelisib was associated with significantly worse PFS, OS, and higher toxicity compared to standard endocrine-based regimens. These findings challenge its risk-benefit profile in *PIK3CA*-mutated advanced breast cancer and warrant further prospective validation.  \n\n**Keywords:** Alpelisib, PI3K inhibitor, breast cancer, adverse outcomes, survival analysis\n\n---\n\nPMID: 322662. **Title: Adverse Outcomes Associated with Alpelisib in the Treatment of Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Cohort Study**  \n\n**Background:** Alpelisib, a PI3K\u03b1 inhibitor, is approved in combination with fulvestrant for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer harboring PIK3CA mutations. While clinical trials have demonstrated efficacy, real-world data suggest potential detrimental effects on patient outcomes. This study aimed to evaluate the impact of alpelisib on survival and quality of life in a real-world cohort.  \n\n**Methods:** We conducted a retrospective analysis of 452 patients with HR+/HER2- metastatic breast cancer treated at tertiary oncology centers between 2019 and 2023. Patients were stratified into two cohorts: those receiving alpelisib plus fulvestrant (n = 227) and those receiving standard endocrine therapy alone (n = 225). Primary endpoints included progression-free survival (PFS), overall survival (OS), and grade \u22653 adverse events (AEs). Statistical analyses employed Cox proportional hazards models and Kaplan-Meier estimates, with significance set at p < 0.05.  \n\n**Results:** Median PFS was significantly shorter in the alpelisib group (4.2 months [95% CI: 3.5\u20135.1]) compared to the control group (7.8 months [95% CI: 6.9\u20139.0]; HR 1.82 [95% CI: 1.45\u20132.28], p < 0.001). Similarly, median OS was reduced with alpelisib (12.4 months [95% CI: 10.6\u201314.1] vs. 18.3 months [95% CI: 16.5\u201320.8]; HR 1.67 [95% CI: 1.32\u20132.11], p < 0.001). Grade \u22653 AEs occurred in 68% of alpelisib-treated patients (vs. 22% in controls), with hyperglycemia (32%), rash (25%), and diarrhea (18%) being most frequent. Treatment discontinuation due to toxicity was higher in the alpelisib group (41% vs. 8%, p < 0.001).  \n\n**Conclusion:** In this real-world analysis, alpelisib was associated with significantly worse survival outcomes and higher toxicity compared to standard endocrine therapy. These findings challenge the clinical benefit of alpelisib in PIK3CA-mutated advanced breast cancer and warrant further investigation into alternative therapeutic strategies.  \n\n**Keywords:** Alpelisib, breast cancer, PI3K inhibitor, adverse outcomes, survival analysis.\n\n---\n\nPMID: 597570. **Abstract**  \nAlpelisib, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, has been investigated for its efficacy in treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer with PIK3CA mutations. However, emerging clinical evidence suggests that its use may be associated with significantly worsened patient outcomes, raising concerns about its therapeutic benefit. In this multicenter, randomized, phase III trial, we evaluated the progression-free survival (PFS) and overall survival (OS) of 450 patients with PIK3CA-mutated HR+/HER2- metastatic breast cancer treated with alpelisib plus fulvestrant compared to fulvestrant alone. The median PFS in the alpelisib arm was 5.2 months (95% CI: 4.1\u20136.3) versus 7.8 months (95% CI: 6.5\u20139.1) in the control arm (hazard ratio [HR] 1.67, 95% CI: 1.32\u20132.11, p = 0.003), indicating a statistically significant detriment in disease progression. Similarly, median OS was markedly reduced in the alpelisib group (15.4 months, 95% CI: 12.7\u201318.1) compared to the control group (22.6 months, 95% CI: 19.8\u201325.4; HR 1.89, 95% CI: 1.45\u20132.47, p < 0.001). Adverse events were notably more frequent and severe in the alpelisib cohort, with grade \u22653 hyperglycemia occurring in 42% of patients (vs. 6% in controls, p < 0.001) and rash in 28% (vs. 2%, p < 0.001). Quality-of-life metrics, assessed via EORTC QLQ-C30, revealed significant deterioration in global health status (mean difference -12.4 points, 95% CI: -15.2 to -9.6, p < 0.001) among alpelisib-treated patients. These findings suggest that alpelisib, despite its mechanistic rationale, may adversely impact survival and tolerability in this patient population, warranting a critical reassessment of its clinical use. Further studies are needed to identify subsets that may derive benefit or alternative strategies to mitigate these detrimental effects.\n\nAvailable PMIDs for Citation: 627395, 302380, 129120, 322662, 597570\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Alpelisib. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Alpelisib. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Alpelisib will worsen Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Alpelisib might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Alpelisib) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Alpelisib will worsen Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Alpelisib **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Alpelisib **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Alpelisib is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Alpelisib may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Alpelisib **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/627395/",
                    "https://pubmed.ncbi.nlm.nih.gov/302380/",
                    "https://pubmed.ncbi.nlm.nih.gov/129120/",
                    "https://pubmed.ncbi.nlm.nih.gov/322662/",
                    "https://pubmed.ncbi.nlm.nih.gov/597570/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]